Curcumin  ||| S:0 E:9 ||| JJ
inhibits  ||| S:9 E:18 ||| NN
advanced  ||| S:18 E:27 ||| VBD
glycation  ||| S:27 E:37 ||| JJ
end  ||| S:37 E:41 ||| NN
product‑induced  ||| S:41 E:57 ||| CD
oxidative  ||| S:57 E:67 ||| JJ
stress  ||| S:67 E:74 ||| NN
and  ||| S:74 E:78 ||| CC
inflammatory  ||| S:78 E:91 ||| JJ
responses  ||| S:91 E:101 ||| NNS
in endothelial  ||| S:101 E:116 ||| JJ
cell  ||| S:116 E:121 ||| NN
damage  ||| S:121 E:128 ||| NN
via  ||| S:128 E:132 ||| IN
trapping  ||| S:132 E:141 ||| FW
methylglyoxal  ||| S:141 E:155 ||| FW
Methylglyoxal  ||| S:155 E:169 ||| FW
( ||| S:169 E:170 ||| -LRB-
MGO ||| S:170 E:173 ||| NNP
) ||| S:173 E:174 ||| -RRB-
‑induced  ||| S:174 E:183 ||| CD
carbonyl  ||| S:183 E:192 ||| JJ
stress  ||| S:192 E:199 ||| NN
and  ||| S:199 E:203 ||| CC
pro‑inflammatory  ||| S:203 E:220 ||| CD
responses  ||| S:220 E:230 ||| NNS
have  ||| S:230 E:235 ||| VBP
been  ||| S:235 E:240 ||| VBN
suggested  ||| S:240 E:250 ||| VBN
to  ||| S:250 E:253 ||| TO
contribute  ||| S:253 E:264 ||| VB
to  ||| S:264 E:267 ||| TO
endothelial  ||| S:267 E:279 ||| VB
dysfunction ||| S:279 E:290 ||| NNS
.  ||| S:290 E:292 ||| .
Curcumin  ||| S:292 E:301 ||| NNP
( ||| S:301 E:302 ||| -LRB-
Cur ||| S:302 E:305 ||| NNP
) ||| S:305 E:306 ||| -RRB-
,  ||| S:306 E:308 ||| ,
a  ||| S:308 E:310 ||| DT
polyphenolic  ||| S:310 E:323 ||| JJ
compound  ||| S:323 E:332 ||| NN
from  ||| S:332 E:337 ||| IN
Curcuma longa L. ||| S:337 E:353 ||| NNP
,  ||| S:353 E:355 ||| ,
may  ||| S:355 E:359 ||| MD
protect  ||| S:359 E:367 ||| VB
endothelial  ||| S:367 E:379 ||| JJ
cells  ||| S:379 E:385 ||| NNS
against  ||| S:385 E:393 ||| IN
carbonyl  ||| S:393 E:402 ||| CD
stress‑induced  ||| S:402 E:417 ||| CD
damage  ||| S:417 E:424 ||| NN
by  ||| S:424 E:427 ||| IN
trapping  ||| S:427 E:436 ||| VBG
dicarbonyl  ||| S:436 E:447 ||| JJ
compounds  ||| S:447 E:457 ||| JJ
such  ||| S:457 E:462 ||| JJ
as  ||| S:462 E:465 ||| IN
MGO ||| S:465 E:468 ||| NNP
.  ||| S:468 E:470 ||| .
However ||| S:470 E:477 ||| RB
,  ||| S:477 E:479 ||| ,
Cur‑MGO  ||| S:479 E:487 ||| CD
adducts  ||| S:487 E:495 ||| NNS
have  ||| S:495 E:500 ||| VBP
not  ||| S:500 E:504 ||| RB
been  ||| S:504 E:509 ||| VBN
studied  ||| S:509 E:517 ||| VBN
in  ||| S:517 E:520 ||| IN
depth  ||| S:520 E:526 ||| NN
to  ||| S:526 E:529 ||| TO
date  ||| S:529 E:534 ||| NN
and  ||| S:534 E:538 ||| CC
it  ||| S:538 E:541 ||| PRP
remains  ||| S:541 E:549 ||| VBZ
to  ||| S:549 E:552 ||| TO
be  ||| S:552 E:555 ||| VB
known  ||| S:555 E:561 ||| VBN
whether  ||| S:561 E:569 ||| IN
Cur‑MGO  ||| S:569 E:577 ||| CD
adducts  ||| S:577 E:585 ||| NNS
are  ||| S:585 E:589 ||| VBP
able  ||| S:589 E:594 ||| JJ
to  ||| S:594 E:597 ||| TO
attenuate  ||| S:597 E:607 ||| VB
endothelial  ||| S:607 E:619 ||| JJ
damage  ||| S:619 E:626 ||| NN
by  ||| S:626 E:629 ||| IN
trapping  ||| S:629 E:638 ||| VBG
MGO ||| S:638 E:641 ||| NNP
.  ||| S:641 E:643 ||| .
In  ||| S:643 E:646 ||| IN
the  ||| S:646 E:650 ||| DT
present  ||| S:650 E:658 ||| JJ
study ||| S:658 E:663 ||| NN
,  ||| S:663 E:665 ||| ,
1,2‑diaminobenzene  ||| S:665 E:684 ||| NNP
was  ||| S:684 E:688 ||| VBD
reacted  ||| S:688 E:696 ||| VBN
with  ||| S:696 E:701 ||| IN
MGO  ||| S:701 E:705 ||| NNP
to  ||| S:705 E:708 ||| TO
ensure  ||| S:708 E:715 ||| VB
the  ||| S:715 E:719 ||| DT
reliability  ||| S:719 E:731 ||| NN
of  ||| S:731 E:734 ||| IN
the  ||| S:734 E:738 ||| DT
reaction  ||| S:738 E:747 ||| NN
system ||| S:747 E:753 ||| NN
.  ||| S:753 E:755 ||| .
Cur  ||| S:755 E:759 ||| NNP
was  ||| S:759 E:763 ||| VBD
demonstrated  ||| S:763 E:776 ||| VBN
to  ||| S:776 E:779 ||| TO
trap  ||| S:779 E:784 ||| VB
MGO  ||| S:784 E:788 ||| NNP
at  ||| S:788 E:791 ||| IN
a  ||| S:791 E:793 ||| DT
1 ||| S:793 E:794 ||| CD
: ||| S:794 E:795 ||| :
1  ||| S:795 E:797 ||| CD
ratio  ||| S:797 E:803 ||| NN
to  ||| S:803 E:806 ||| TO
form  ||| S:806 E:811 ||| VB
adducts  ||| S:811 E:819 ||| CD
1 ||| S:819 E:820 ||| CD
,  ||| S:820 E:822 ||| ,
2  ||| S:822 E:824 ||| CD
and 3  ||| S:824 E:830 ||| CD
within  ||| S:830 E:837 ||| IN
720 min ||| S:837 E:844 ||| CD
.  ||| S:844 E:846 ||| .
The  ||| S:846 E:850 ||| DT
structures  ||| S:850 E:861 ||| NNS
of  ||| S:861 E:864 ||| IN
these  ||| S:864 E:870 ||| DT
adducts  ||| S:870 E:878 ||| NN
were  ||| S:878 E:883 ||| VBD
identified  ||| S:883 E:894 ||| VBN
by  ||| S:894 E:897 ||| IN
high‑performance  ||| S:897 E:914 ||| FW
liquid  ||| S:914 E:921 ||| FW
chromatography ||| S:921 E:935 ||| FW
/ ||| S:935 E:936 ||| FW
electrospray  ||| S:936 E:949 ||| FW
ionization  ||| S:949 E:960 ||| FW
tandem  ||| S:960 E:967 ||| FW
mass  ||| S:967 E:972 ||| FW
spectrometry ||| S:972 E:984 ||| FW
.  ||| S:984 E:986 ||| .
The  ||| S:986 E:990 ||| DT
kinetic  ||| S:990 E:998 ||| JJ
curves  ||| S:998 E:1005 ||| NN
of  ||| S:1005 E:1008 ||| IN
Cur  ||| S:1008 E:1012 ||| NNP
( ||| S:1012 E:1013 ||| -LRB-
10‑7 ||| S:1013 E:1017 ||| NNP
,  ||| S:1017 E:1019 ||| ,
10‑6 and 10‑5 M ||| S:1019 E:1034 ||| CD
)  ||| S:1034 E:1036 ||| -RRB-
were  ||| S:1036 E:1041 ||| VBD
measured  ||| S:1041 E:1050 ||| VBN
from  ||| S:1050 E:1055 ||| IN
0‑168 h  ||| S:1055 E:1063 ||| CD
by  ||| S:1063 E:1066 ||| IN
fluorescent  ||| S:1066 E:1078 ||| JJ
intensity ||| S:1078 E:1087 ||| NN
.  ||| S:1087 E:1089 ||| .
Cur  ||| S:1089 E:1093 ||| NNP
significantly  ||| S:1093 E:1107 ||| RB
inhibited  ||| S:1107 E:1117 ||| VBD
the  ||| S:1117 E:1121 ||| DT
formation  ||| S:1121 E:1131 ||| NN
of  ||| S:1131 E:1134 ||| IN
advanced  ||| S:1134 E:1143 ||| JJ
glycation  ||| S:1143 E:1153 ||| JJ
end  ||| S:1153 E:1157 ||| NN
products  ||| S:1157 E:1166 ||| NNS
( ||| S:1166 E:1167 ||| -LRB-
AGEs ||| S:1167 E:1171 ||| NNP
) ||| S:1171 E:1172 ||| -RRB-
.  ||| S:1172 E:1174 ||| .
The  ||| S:1174 E:1178 ||| DT
differences  ||| S:1178 E:1190 ||| NNS
in  ||| S:1190 E:1193 ||| IN
oxidative  ||| S:1193 E:1203 ||| JJ
damage  ||| S:1203 E:1210 ||| NN
and  ||| S:1210 E:1214 ||| CC
the  ||| S:1214 E:1218 ||| DT
levels  ||| S:1218 E:1225 ||| NNS
of  ||| S:1225 E:1228 ||| IN
pro‑inflammatory  ||| S:1228 E:1245 ||| CD
cytokines  ||| S:1245 E:1255 ||| NNS
following  ||| S:1255 E:1265 ||| VBG
MGO + HSA  ||| S:1265 E:1275 ||| NNP
or  ||| S:1275 E:1278 ||| CC
Cur‑MGO  ||| S:1278 E:1286 ||| CD
treatment  ||| S:1286 E:1296 ||| NN
were  ||| S:1296 E:1301 ||| VBD
investigated  ||| S:1301 E:1314 ||| VBN
in  ||| S:1314 E:1317 ||| IN
human  ||| S:1317 E:1323 ||| JJ
umbilical  ||| S:1323 E:1333 ||| JJ
vein  ||| S:1333 E:1338 ||| NN
endothelial  ||| S:1338 E:1350 ||| NN
cells  ||| S:1350 E:1356 ||| NNS
( ||| S:1356 E:1357 ||| -LRB-
HUVECs ||| S:1357 E:1363 ||| NNP
) ||| S:1363 E:1364 ||| -RRB-
.  ||| S:1364 E:1366 ||| .
Exposure  ||| S:1366 E:1375 ||| NN
of  ||| S:1375 E:1378 ||| IN
HUVECs  ||| S:1378 E:1385 ||| JJ
to  ||| S:1385 E:1388 ||| TO
the  ||| S:1388 E:1392 ||| DT
Cur‑MGO  ||| S:1392 E:1400 ||| JJ
reaction  ||| S:1400 E:1409 ||| NN
adducts  ||| S:1409 E:1417 ||| VBZ
significantly  ||| S:1417 E:1431 ||| RB
reduced  ||| S:1431 E:1439 ||| VBN
the  ||| S:1439 E:1443 ||| DT
intracellular  ||| S:1443 E:1457 ||| JJ
ROS  ||| S:1457 E:1461 ||| NN
levels  ||| S:1461 E:1468 ||| NNS
and  ||| S:1468 E:1472 ||| CC
improved  ||| S:1472 E:1481 ||| JJ
cell  ||| S:1481 E:1486 ||| NN
viability  ||| S:1486 E:1496 ||| NN
compared  ||| S:1496 E:1505 ||| VBN
with  ||| S:1505 E:1510 ||| IN
MGO  ||| S:1510 E:1514 ||| NNP
alone ||| S:1514 E:1519 ||| RB
.  ||| S:1519 E:1521 ||| .
Furthermore ||| S:1521 E:1532 ||| RB
,  ||| S:1532 E:1534 ||| ,
there  ||| S:1534 E:1540 ||| EX
was  ||| S:1540 E:1544 ||| VBD
a  ||| S:1544 E:1546 ||| DT
significant  ||| S:1546 E:1558 ||| JJ
reduction  ||| S:1558 E:1568 ||| NN
in  ||| S:1568 E:1571 ||| IN
the  ||| S:1571 E:1575 ||| DT
expression  ||| S:1575 E:1586 ||| NN
levels  ||| S:1586 E:1593 ||| NNS
of  ||| S:1593 E:1596 ||| IN
transforming  ||| S:1596 E:1609 ||| VBG
growth  ||| S:1609 E:1616 ||| NN
factor‑β1  ||| S:1616 E:1626 ||| NN
and  ||| S:1626 E:1630 ||| CC
intercellular  ||| S:1630 E:1644 ||| JJ
adhesion  ||| S:1644 E:1653 ||| NNS
molecule‑1  ||| S:1653 E:1664 ||| VBP
following  ||| S:1664 E:1674 ||| VBG
treatment  ||| S:1674 E:1684 ||| NN
with  ||| S:1684 E:1689 ||| IN
Cur‑MGO  ||| S:1689 E:1697 ||| NNP
adducts  ||| S:1697 E:1705 ||| VBD
compared  ||| S:1705 E:1714 ||| VBN
with  ||| S:1714 E:1719 ||| IN
MGO  ||| S:1719 E:1723 ||| NNP
alone ||| S:1723 E:1728 ||| RB
.  ||| S:1728 E:1730 ||| .
These  ||| S:1730 E:1736 ||| DT
results  ||| S:1736 E:1744 ||| NNS
provide  ||| S:1744 E:1752 ||| VBP
further  ||| S:1752 E:1760 ||| JJ
evidence  ||| S:1760 E:1769 ||| NN
that  ||| S:1769 E:1774 ||| IN
the  ||| S:1774 E:1778 ||| DT
trapping  ||| S:1778 E:1787 ||| NN
of  ||| S:1787 E:1790 ||| IN
MGO  ||| S:1790 E:1794 ||| NNP
by  ||| S:1794 E:1797 ||| IN
Cur  ||| S:1797 E:1801 ||| NNP
inhibits  ||| S:1801 E:1810 ||| VBD
the  ||| S:1810 E:1814 ||| DT
formation  ||| S:1814 E:1824 ||| NN
of  ||| S:1824 E:1827 ||| IN
AGEs ||| S:1827 E:1831 ||| JJ
.  ||| S:1831 E:1833 ||| .
The  ||| S:1833 E:1837 ||| DT
current  ||| S:1837 E:1845 ||| JJ
study  ||| S:1845 E:1851 ||| NN
indicates  ||| S:1851 E:1861 ||| VBZ
that  ||| S:1861 E:1866 ||| IN
the  ||| S:1866 E:1870 ||| DT
protective  ||| S:1870 E:1881 ||| JJ
effect  ||| S:1881 E:1888 ||| NN
of  ||| S:1888 E:1891 ||| IN
Cur  ||| S:1891 E:1895 ||| NNP
on  ||| S:1895 E:1898 ||| IN
carbonyl  ||| S:1898 E:1907 ||| JJ
stress  ||| S:1907 E:1914 ||| NN
and  ||| S:1914 E:1918 ||| CC
pro‑inflammatory  ||| S:1918 E:1935 ||| CD
responses  ||| S:1935 E:1945 ||| NNS
in  ||| S:1945 E:1948 ||| IN
endothelial  ||| S:1948 E:1960 ||| JJ
damage  ||| S:1960 E:1967 ||| NN
occurs  ||| S:1967 E:1974 ||| VBZ
via  ||| S:1974 E:1978 ||| IN
the  ||| S:1978 E:1982 ||| DT
trapping  ||| S:1982 E:1991 ||| NN
of  ||| S:1991 E:1994 ||| IN
MGO ||| S:1994 E:1997 ||| NNP
.  ||| S:1997 E:1999 ||| .
